Recent NUWE News
- New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy • GlobeNewswire Inc. • 08/27/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:45:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/24/2024 01:31:56 AM
- Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 08/23/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 05:00:16 PM
- Nuwellis, Inc. Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 01:15:42 PM
- Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions • GlobeNewswire Inc. • 08/08/2024 01:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/02/2024 08:12:11 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2024 07:05:58 PM
- Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s • GlobeNewswire Inc. • 07/26/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2024 01:25:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:31:38 PM
- Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/24/2024 12:02:35 PM
- Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024 • GlobeNewswire Inc. • 07/23/2024 08:10:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 07/17/2024 08:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 01:12:51 PM
- Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s • GlobeNewswire Inc. • 07/17/2024 01:00:00 PM
- SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner • GlobeNewswire Inc. • 07/12/2024 12:30:00 PM
- New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference • GlobeNewswire Inc. • 07/09/2024 01:00:00 PM
- Nuwellis Announces Reverse Stock Split • GlobeNewswire Inc. • 06/26/2024 12:45:00 PM
- Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™ • GlobeNewswire Inc. • 06/25/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:15:22 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM